Table 3 Frequencies of KIR genes in the presence of their ligands HLA Class I in patients with leprosy and their clinical forms and healthy individuals in the population of Rondonópolis, MT
KIR – HLA Class I | Per se | LL | Borderline | TT | Controls |
|---|---|---|---|---|---|
N = 408 | N = 21 | N = 302 | N = 60 | N = 413 | |
n (%) | n (%) | n (%) | n (%) | n (%) | |
KIR2DL1 – C2 | 173 (42.4) | 10 (47.6) | 121 (40.0) | 29 (48.3) | 188 (45.5) |
KIR2DL1 – C2/C2 | 82 (20.0) | 5 (23.8) | 59 (19.5) | 14 (23.3) | 79 (19.1) |
KIR2DL2 – C1 | 145 (35.5) | 8 (38.0) | 95 (31.4) | 27 (45.0) | 134 (32.4) |
KIR2DL2 – C1/C1 | 71 (17.4) | 2 (9.52) | 56 (18.5) | 11 (18.3) | 95 (23.0) |
KIR2DL3 – C1 | 174 (42.6) | 9 (42.8) | 128 (42.3) | 26 (43.3) | 184 (44.5) |
KIR2DL3 – C1/C1 | 92 (22.5) | 3 (14.2) | 71 (23.5) | 13 (21.6) | 116 (28.0) |
KIR3DL1 – Bw4 | 153 (37.5) | 7 (33.3) | 118 (39.0) | 18 (30.0) | 164 (39.7) |
KIR3DL1 – Bw4/Bw4 | 44 (10.7) | 2 (9.52) | 33 (10.9) | 7 (11.6) | 54 (13.0) |
KIR3DL2 – A*03/*11 | 99 (24.2) | 4 (19.0) | 74 (24.5) | 15 (25.0) | 86 (20.8) |
KIR2DS1 – C2 | 70 (17.1) | 2 (9.52) | 48 (15.8) | 14 (23.3) | 74 (17.9) |
KIR2DS1 – C2/C2 | 38 (9.31) | 2 (9.52) | 27 (8.94) | 7 (11.6) | 25 (6.05) |
KIR2DS2 – C1 | 111 (27.2)a | 5 (23.8) | 74 (24.5) | 20 (33.3)a | 85 (20.5)a |
KIR2DS2 – C1/C1 | 51 (12.5) | 3 (14.2) | 39 (12.9) | 6 (10.0) | 60 (14.5) |
KIR3DS1 – Bw4 | 57 (13.9) | 1 (4.76) | 46 (15.2) | 7 (11.6) | 59 (14.2) |
KIR3DS1 – Bw4/Bw4 | 21 (5.14) | 1 (4.76) | 16 (5.29) | 4 (6.66) | 23 (5.56) |
KIR2DL2/2DL2 – C1 | 22 (5.39)b | 3 (14.2)b | 10 (3.31)b | 5 (8.33)b | 9 (2.17)b |
KIR2DL2/2DL2 – C1/C1 | 14 (3.43) | 0 (0.0) | 11 (3.64) | 2 (3.33) | 10 (2.42) |
KIR2DL2/2DL3 – C1 | 122 (29.9) | 6 (28.5) | 88 (29.1) | 19 (31.6) | 124 (30.0) |
KIR2DL2/2DL3 – C1/C1 | 56 (13.7)c | 2 (9.52) | 43 (14.2) | 11 (18.3) | 82 (19.8)c |
KIR2DL3/2DL3 – C1 | 55 (13.4) | 4 (19.0) | 44 (14.5) | 5 (8.33) | 62 (15.0) |
KIR2DL3/2DL3 – C1/C1 | 34 (8.33) | 1 (4.76) | 25 (8.27) | 4 (6.66) | 32 (7.74) |